Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning. Today, we exclusively write about how politics are shaping the new FDA voucher program, see how the U.K. might buoy U.S. science with renewed investment, and more.
The need-to-know this morning
- BioMarin said it is acquiring Amicus Therapeutics, maker of rare-disease drugs, for $4.8 billion.
FDA voucher program enables political influence in science, staffers say
A new FDA program meant to speed drug reviews is becoming a vehicle for political interference, STAT’s Lizzy Lawrence reports exclusively.
Continue to STAT+ to read the full story…